Author

S. O. Mueller

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 5 Organism:mouse· 3 Research Focus:drug response / drug discovery· 2 Organism:rat· 2 Assay:bulk RNA-seq· 1 Organism:non-human primate· 1 Research Focus:variant effect prediction· 1

Frequent Co-Authors

B. Petsch· 5 shared S. Rauch· 5 shared N. Roth· 4 shared D. Hoffmann· 3 shared A. Dorhoi· 2 shared B. Corleis· 2 shared C. Fricke· 2 shared J. Schoen· 2 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersImmunology

B. Petsch

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Low-dose bivalent mRNA vaccine is highly effective against different SARS-CoV-2 variants in a transgenic mouse model

B. Corleis, D. Hoffmann, S. Rauch, C. Fricke, N. Roth, J. Gergen, K. Kovacikova, K. Schlottau, N. J. Halwe, L. Ulrich, J. Schön, K. Wernike, M. Widera, S. Ciesek, S. O. Mueller, , A. Dorhoi

This study shows a low-dose bivalent mRNA vaccine targeting multiple SARS-CoV-2 variants provides strong protection in mice and rats, with comparable antibody levels and reduced viral replication.

bioRxiv · Apr 20, 2022 · PreprintImmunology

Optimised non-coding regions of mRNA SARS-CoV-2 vaccine CV2CoV improves homogeneous and heterogenous neutralising antibody responses

N. Roth, J. Schoen, D. Hoffmann, M. Thran, A. Thess, S. O. Mueller, B. Petsch, S. Rauch

This study compares two mRNA vaccines, CVnCoV and CV2CoV, showing CV2CoV induces higher neutralizing antibody titers and cross-neutralization against variants in rats.

bioRxiv · May 13, 2021 · PreprintImmunology

CVnCoV protects human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2

D. Hoffmann, B. Corleis, S. Rauch, N. Roth, J. Muehe, N. J. Halwe, L. Ulrich, C. Fricke, J. Schoen, A. Kraft, A. Breithaupt, K. Wernike, A. Michelitsch, F. Sick, C. Wylezich, , M. Beer

This study evaluates the efficacy of the CVnCoV mRNA vaccine against ancestral and emerging SARS-CoV-2 variants in a human ACE2 transgenic mouse model, showing complete protection against B.1.351.

bioRxiv · Mar 22, 2021Microbiology

mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection

S. Rauch, K. E. Gooch, Y. Hall, F. J. Salguero, M. J. Dennis, F. V. Gleeson, D. Harris, C. Ho, H. E. Humphries, S. Longet, D. Ngabo, J. Paterson, E. L. Rayner, K. A. Ryan, S. Sharpe, , M. W. Carroll

This study shows that the mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 infection and reduces disease severity.

bioRxiv · Dec 23, 2020 · PreprintImmunology

mRNA based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus neutralizing antibodies and mediates protection in rodents

S. Rauch, N. Roth, K. Schwendt, M. Fotin-Mleczek, S. O. Mueller, B. Petsch

This study shows that the mRNA vaccine CVnCoV induces strong neutralizing antibodies and protects hamsters from SARS-CoV-2 infection.

bioRxiv · Oct 23, 2020Immunology